TransCon hGH
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency, Pediatric
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Trial Timeline
Nov 13, 2017 → Mar 19, 2019
NCT ID
NCT03305016About TransCon hGH
TransCon hGH is a phase 3 stage product being developed by Ascendis Pharma for Growth Hormone Deficiency, Pediatric. The current trial status is completed. This product is registered under clinical trial identifier NCT03305016. Target conditions include Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03344458 | Phase 3 | Completed |
| NCT03305016 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency, Pediatric